Light Mode
$8.48 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.48, $0.69 below the day’s high of $9.17
+5.08 (+149.41%) / 6M
Momentum, market sentiment, and recent alerts
IOVA reads poor: price sits above one of the two key moving averages, the 12-month move is +334.9%.
No alerts for IOVA in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.